{
  "image_filename": "figure_p2_mrg_det_1_000.png",
  "image_path": "Liu_et_al.__2024_/extracted/figures/figure_p2_mrg_det_1_000.png",
  "image_type": "Figure",
  "page_number": 2,
  "block_id": "mrg_det_1_000",
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "supports_claim": true,
  "explanation": "CONSORT flow diagram for Year 1 (2018\u20132019) showing 723 participants randomized into four vaccine arms: ccIIV4 (n=283), RIV4 (n=198), Fluzone IIV4 (n=122), and Fluarix IIV4 (n=120). Evidence: The allocation boxes list RIV4 (recombinant-hemagglutinin influenza vaccine quadrivalent, i.e., Flublok) versus Fluarix IIV4 (quadrivalent standard-dose) in the same pivotal trial. The diagram supports the claim by directly showing RIV4 (Flublok) evaluated against Fluarix IIV4 in the randomized trial.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": true,
    "image_description": "CONSORT flow diagram for Year 1 (2018\u20132019) showing 723 participants randomized into four vaccine arms: ccIIV4 (n=283), RIV4 (n=198), Fluzone IIV4 (n=122), and Fluarix IIV4 (n=120).",
    "evidence_found": "The allocation boxes list RIV4 (recombinant-hemagglutinin influenza vaccine quadrivalent, i.e., Flublok) versus Fluarix IIV4 (quadrivalent standard-dose) in the same pivotal trial.",
    "reasoning": "The diagram supports the claim by directly showing RIV4 (Flublok) evaluated against Fluarix IIV4 in the randomized trial.",
    "confidence_notes": null
  }
}